Novavax says its COVID-19 vaccine appears 89% effective, based on early findings from a British study. According to USA Today, the two-dose vaccine was just 60% effective in the South African trial.
Novavax Inc. said this week that its COVID-19 vaccine would not receive regulatory clearance in the U.S. or the U.K. until at least July, while a shortage of materials has delayed its production ...
Hosted on MSN
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
Novavax, Inc. (NVAX) announced on Thursday that its COVID-19 vaccine, Nuvaxovid, has been approved in Japan, triggering a milestone payment from Japanese pharmaceutical company Takeda. The vaccine was ...
LONDON (AP) - Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not quite as well — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results